BioSpace News Archive

Daxor Corporation, the global leader in blood volume measurement technology, announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure.

SyntheX, Inc., an emerging growth biotechnology company innovating next-generation functional drug discovery engines, announced a research collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize novel small molecules using SyntheX’s ToRNeDO platform for protein degradation.

Sionna Therapeutics today announced that it will present preclinical data on novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations at the Cystic Fibrosis Foundation’s North American Cystic Fibrosis Conference (NACFC) 2022 to be held November 3-5 at the Pennsylvania Convention Center in Philadelphia.

IVERIC bio, Inc. reported that on October 3, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

Incyte announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors.

Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, announced that it received notice from The Nasdaq Stock Market LLC on October 3, 2022 informing Sonnet that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Quantum-Si Incorporated, a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, announced the appointment of Jeff Hawkins as Chief Executive Officer.

Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.

RenovoRx, Inc., a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion therapy platform, announced management’s participation in two upcoming investor conferences this month.

Myrtelle Inc., a gene therapy company focused on developing transformative treatments for neurodegenerative diseases, announced the completion of dosing of 8 patients with the Company’s recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease.